BioStem Technologies (BSEM) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Passage Bio (PASG) has outperformed BioStem Technologies (BSEM) over the past year, losing 49.3% versus a loss of 84.0%. Over five years, BSEM leads with a -55.9% price change compared with -97.3% for PASG. Passage Bio is the larger company by market cap ($12.6 million vs $12.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | PASG |
|---|---|---|
| Share price | $0.6351 | $3.92 |
| Market cap | $12.18M | $12.61M |
| 1-day change | -10.23% | +11.68% |
| YTD return | -83.33% | -66.78% |
| 1-year return | -83.98% | -49.32% |
| 5-year return | -55.90% | -97.30% |
| P/E ratio (TTM) | 0.72 | — |
| Forward P/E | 2.19 | — |
| EPS (TTM) | $0.88 | $-10.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-45.52M |
| 52-week high | $8.40 | $20.00 |
| 52-week low | $0.5347 | $3.29 |
| Distance from 52-week high | -92.44% | -80.40% |
| Analyst consensus | none | buy |
| Avg. price target upside | +1002.19% | +295.41% |
| Average volume | 194.93K | 20.77K |
| Shares outstanding | 19.18M | 3.22M |
| Employees | 73 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PASG has outperformed BSEM by 34.7 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
BSEM vs PASG FAQ
Which is bigger, BioStem Technologies or Passage Bio?
Passage Bio (PASG) is larger, with a market capitalization of $12.61M compared with $12.18M for BioStem Technologies (BSEM).
Which stock has performed better over the past year, BSEM or PASG?
PASG returned -49.32% over the past 12 months, compared with -83.98% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Passage Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.